ERBB2 and breast carcinoma: Previous preclinical studies have observed that [18F]-FMISO PET imaging can longitudinally quantify significant reductions in tumor hypoxia and predict response to trastuzumab in mouse models of HER2+ breast cancer prior to significant changes in tumor volume [18,19].